Andy Roddick defends Serena Williams' GLP-1 weight loss amid comeback talk

Former tennis star Andy Roddick has voiced support for Serena Williams' use of GLP-1 medication in her weight-loss efforts, suggesting it could aid a potential return to the court. Williams has shared how the treatment improved her health, while speculation grows following her inclusion in the anti-doping pool and practice sessions with younger players. Roddick emphasized the benefits for injury prevention during training.

In a recent episode of the Served podcast, Andy Roddick addressed criticism of Serena Williams' use of GLP-1 medication for weight loss. He stated that if he were attempting a comeback, he would prioritize rapid weight reduction to facilitate safer training. "I can tell you something that I think I know for a fact, right? I’m not Serena. I can’t play anymore. I stink. And if I decided that I wanted to come back, guess what I would be doing immediately? Immediately, I’d be dropping 20 pounds as fast as I can," Roddick said.

Roddick argued that starting lighter reduces injury risks during preparation, which is a major hurdle for returning athletes. "I would be taking those drugs because you know what becomes easier when you are 20 pounds lighter? Actually, getting back to the training that you need without getting injured to get back on tour," he explained. He added, "What it does is shortens the timeline for training and mitigates a lot of the risk in because the thing with getting back is like you get injured training, injured training, injured training, you can’t get back. Right."

Williams first discussed her use of the medication in an August 2025 interview with People Magazine and reinforced it in a Super Bowl XL advertisement in 2026. In a January 2026 interview with Today.com, she highlighted health improvements: "My blood sugar is better. I was able to lower my cholesterol by 30%. Some of these numbers [previous high cholesterol levels] are from when I was literally winning Grand Slams. It wasn’t, like, just playing tennis. I was dominating. I was at risk for heart disease, and I didn’t even know. … That’s scary."

Comeback rumors intensified after Williams' name appeared in the tennis anti-doping testing pool, a step often required for returning players. On the Today show in January 2026, she responded ambiguously: "I’m just having fun and enjoying my life right now," adding, "I don’t know, I’m just going to see what happens."

American player Alycia Parks recently practiced with Williams and commented on her fitness. "I actually practiced with her last Monday. And I messaged her yesterday. She’s definitely a good mentor to me, and she’s helped me a lot, especially in my practices," Parks told Tennis Majors. She added, "She is in great shape. So I think she would kill it on tour."

Support for Williams continues to build in the tennis community as discussions of a potential return, possibly emulating sister Venus, persist.

Mga Kaugnay na Artikulo

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
Larawang ginawa ng AI

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Iniulat ng AI Larawang ginawa ng AI Fact checked

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Alycia Parks, after her first-round win at the Miami Open, provided insights into Serena Williams' current tennis form from their practice sessions. The world No. 105 described Williams as fit and hitting well, though she remains uncertain about any professional comeback. Parks credits the sessions for boosting her own game.

Iniulat ng AI

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Iniulat ng AI Fact checked

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

Gumagamit ng cookies ang website na ito

Gumagamit kami ng cookies para sa analytics upang mapabuti ang aming site. Basahin ang aming patakaran sa privacy para sa higit pang impormasyon.
Tanggihan